Table 2 Prevalence and prognostic significance of clinically relevant gene mutations in the cohort (n = 28)
Gene | N (%) | Median OS (months) | |||
|---|---|---|---|---|---|
Mutant | Wild-type | Hazard ratio | p value | ||
H3F3A | 20 (71%) | 11 | 15 | 1.00 | 1.00 |
HIST1H3B | 7 (25%) | 15 | 11 | 1.20 | 0.69 |
TP53 | 13 (46%) | 12 | 11 | 0.71 | 0.39 |
ACVR1 | 8 (29%) | 11.5 | 11.5 | 1.55 | 0.32 |
PDGFRA | 1 (4%) | 24 | 11 | 0.45 | 0.43 |
ATM | 1 (4%) | 19 | 11 | 0.52 | 0.52 |
PIK3CA | 6 (21%) | 11.5 | 11.5 | 1.46 | 0.45 |
PIK3R1 | 4 (14%) | 14.5 | 11.5 | 0.85 | 0.77 |
ARTX | 3 (11%) | 11 | 12 | 1.40 | 0.59 |
PPM1D | 3 (11%) | 11 | 12 | 0.81 | 0.74 |
BCOR | 2 (7%) | 46 | 11.5 | 0.25 | 0.19 |
BCORL1 | 2 (7%) | 23.5 | 11 | 0.45 | 0.29 |
MET | 2 (7%) | 7 | 12 | 6.20 | 0.03 |
OR7E24 | 3 (11%) | 32 | 11 | 0.11 | 0.04 |
SRGAP3 | 5 (18%) | 10 | 12 | 2.90 | 0.05 |
HLA-B | 3 (11%) | 32 | 11 | 0.14 | 0.06 |
HLA-C | 3 (11%) | 32 | 11 | 0.13 | 0.05 |